| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14728222.2012.703657 |
| P698 | PubMed publication ID | 22793382 |
| P50 | author | Juan A Moreno | Q52356845 |
| Luis M Blanco-Colio | Q55542660 | ||
| Alberto Ortiz | Q56855135 | ||
| P2093 | author name string | Jesús Egido | |
| Alfonso Rubio-Navarro | |||
| Carmen Gómez-Guerrero | |||
| Cristina Sastre | |||
| Sara Moreno | |||
| P2860 | cites work | Structure and Functional Expression of a Human Interleukin-8 Receptor | Q24319897 |
| Fractalkine in vascular biology: from basic research to clinical disease | Q28206445 | ||
| Roles of SLC/CCL21 and CCR7 in human kidney for mesangial proliferation, migration, apoptosis, and tissue homeostasis | Q28215582 | ||
| Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1 | Q28363418 | ||
| Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury | Q28365738 | ||
| Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study | Q28481687 | ||
| Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development | Q28512895 | ||
| Mononuclear cell-infiltrate inhibition by blocking macrophage-derived chemokine results in attenuation of developing crescentic glomerulonephritis | Q28567754 | ||
| Urinary levels of interleukin-8 (IL-8) and disease activity in patients with IgA nephropathy. | Q31913427 | ||
| Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism | Q33574947 | ||
| Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities | Q33676765 | ||
| Induction of B7-1 in podocytes is associated with nephrotic syndrome | Q33785088 | ||
| Chemokines and cell migration in secondary lymphoid organs | Q33807114 | ||
| Expression of chemokines and chemokine receptors during human renal transplant rejection | Q33936064 | ||
| When renal allografts turn DARC. | Q34190915 | ||
| CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome | Q45166206 | ||
| Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. | Q45269853 | ||
| Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria | Q45862407 | ||
| SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. | Q45915598 | ||
| Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. | Q46100164 | ||
| Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor | Q46135127 | ||
| Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice | Q46256014 | ||
| Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion | Q46445286 | ||
| DNA vaccination with naked DNA encoding MCP-1 and RANTES protects against renal injury in adriamycin nephropathy | Q46480431 | ||
| The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease | Q46558237 | ||
| Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. | Q48026114 | ||
| An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. | Q51778397 | ||
| Renal TLR4 mRNA expression correlates with inflammatory marker MCP-1 and profibrotic molecule TGF-β₁ in patients with chronic kidney disease. | Q52894668 | ||
| Involvement of ERK pathway in albumin-induced MCP-1 expression in mouse proximal tubular cells. | Q53383865 | ||
| Interaction between proximal tubular epithelial cells and infiltrating monocytes/T cells in the proteinuric state. | Q53575449 | ||
| The expression of monocyte chemoattractant protein-1 and C-C chemokine receptor 2 in post-kidney transplant patients and the influence of simvastatin treatment. | Q53617394 | ||
| Antiproteinuric Effect of Chemokine C-C Motif Ligand 2 Inhibition in Subjects with Acute Proliferative Lupus Nephritis | Q57702074 | ||
| Protein traffic activates NF-kB gene signaling and promotes MCP-1–dependent interstitial inflammation | Q57703672 | ||
| Cytokine-induced neutrophil chemoattractant mediates neutrophil influx in immune complex glomerulonephritis in rat | Q34235829 | ||
| Chemokines and the molecular basis of cancer metastasis | Q34369211 | ||
| The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis | Q34662335 | ||
| CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis | Q35083458 | ||
| Pathophysiology of proteinuria | Q35083600 | ||
| The GHS-R blocker D-[Lys3] GHRP-6 serves as CCR5 chemokine receptor antagonist. | Q35567355 | ||
| Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function | Q35588337 | ||
| Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells | Q35698582 | ||
| Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis | Q35757157 | ||
| CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5 | Q35911313 | ||
| CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant | Q35956560 | ||
| Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial | Q36084912 | ||
| Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists | Q36351689 | ||
| ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets | Q36486423 | ||
| Efficient renal recruitment of macrophages and T cells in mice lacking the duffy antigen/receptor for chemokines. | Q37257139 | ||
| The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. | Q37264349 | ||
| Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. | Q37415334 | ||
| Chemokine receptor antagonists: part 2. | Q37481304 | ||
| Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential | Q37670253 | ||
| NF-kappaB in renal inflammation | Q37774798 | ||
| Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy | Q37780781 | ||
| A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916. | Q37936463 | ||
| MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-kappaB and activating protein-1. | Q38288712 | ||
| TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation | Q39406226 | ||
| Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo | Q39741161 | ||
| Rosiglitazone activation of PPARgamma suppresses fractalkine signaling | Q39784440 | ||
| Albumin induces endoplasmic reticulum stress and apoptosis in renal proximal tubular cells | Q40235169 | ||
| Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. | Q40425124 | ||
| Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways | Q40630754 | ||
| CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration | Q40646095 | ||
| Expression of functional CCR and CXCR chemokine receptors in podocytes | Q40726391 | ||
| Molecular determinants of receptor binding and signaling by the CX3C chemokine fractalkine. | Q40795533 | ||
| Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. | Q41854872 | ||
| Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy | Q42223007 | ||
| Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis | Q42722219 | ||
| CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice | Q42945868 | ||
| Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate | Q42956746 | ||
| Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis | Q43143097 | ||
| Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. | Q43286010 | ||
| Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells | Q44174264 | ||
| Proteinuria and the risk of developing end-stage renal disease | Q44358762 | ||
| Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury | Q44692955 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 833-845 | |
| P577 | publication date | 2012-08-01 | |
| P1433 | published in | Expert Opinion on Therapeutic Targets | Q5421214 |
| P1476 | title | Targeting chemokines in proteinuria-induced renal disease | |
| P478 | volume | 16 |
| Q38895003 | Gremlin regulates renal inflammation via the vascular endothelial growth factor receptor 2 pathway. |
| Q26799443 | Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade |
| Q34505510 | Identification of aberrant gene expression associated with aberrant promoter methylation in primordial germ cells between E13 and E16 rat F3 generation vinclozolin lineage |
| Q33611989 | Inflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son". |
| Q38756737 | Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease. |
| Q30235846 | Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. |
| Q26864133 | Present and future in the treatment of diabetic kidney disease |
| Q38188747 | Role of chemokines in proteinuric kidney disorders |
| Q40812992 | TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2. |
| Q38857166 | Targeting inflammation in diabetic kidney disease: early clinical trials |
| Q38209811 | Therapeutic approaches to diabetic nephropathy--beyond the RAS. |
Search more.